Welcome to the e-CCO Library!

P578: Therapeutic strategies in the approach of paradoxical psoriasis in IBD: experience of a centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Santos*1, V. Gamelas2, D. Carvalho2, C. Bernardes2, J. Saiote2, J. Ramos2

Created: Friday, 22 February 2019, 9:41 AM
P578: Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort series
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.E. Stellingwerf1*, S. Sahami1, D.C. Winter2, H.E. Mulcahy2, G. Doherty2, G. Cullen2, S. Martin2, G.R. D'Haens3, W.A. Bemelman1, C.J. Buskens1

Created: Thursday, 21 February 2019, 9:14 AM
P579 Randomised open-label controlled trial of ciprofloxacin/doxycycline/hydroxychloroquine combination compared with standard budesonide in active Crohn’s disease (APRICOT)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.M. Rhodes1, S. Subramanian2, P. Flanagan3, G. Horgan4, K. Martin2, J. Mansfield5, M. Parkes6, A. Hart7, H. Dallal8, T. Iqbal9, J. Butterworth10, K. Culshaw11, C. Probert1

Created: Thursday, 30 January 2020, 10:12 AM
P579: Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zambrano Perez A.*1, Elawad M.2, Kiparissi F.1, Shah N.1, Chadokufa S.1, Sider S.1, Huggett B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P579: Online Education Significantly Improved Gastroenterologists' Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Bell, E.(1);Calle, M.(2);Vermeire, S.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P579: Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease
Year: 2022
Source: ECCO'22
Authors: Derikx, L.(1,2);Plevris, N.(2);Su, S.(2);Gros, B.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cook, N.(3,4);Jenkinson, P.(2);O'Hare, C.(2);Merchant, L.(2);Noble, C.(2);Arnott, I.(2);Jones, G.(2,5);Lees, C.(2,4);
Created: Friday, 11 February 2022, 3:56 PM
P579: Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Buisson, A.(1)*;Serrero, M.(2);Altwegg, R.(3);Guilmoteau, T.(1);Bouguen, G.(4);Nachury, M.(5);Amiot, A.(6);Vuitton, L.(7);Treton, X.(8);Caillo, L.(9);Pereira, B.(10);Fumery, M.(11);
Created: Friday, 14 July 2023, 11:05 AM
P579: Risk of CMV reactivation in UC patients with previous history of CMV infection following infliximab or vedolizumab treatments
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Hommel1*, X. Roblin2,3, L. Brichet2,3, B. Bihin4, S. Pillet3,5, J.-F. Rahier1

Created: Thursday, 21 February 2019, 9:14 AM
P579: Wearable Devices Can Predict Disease Activity in inflammatory bowel disease Patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. H. Sossenheimer*1, O. V. Yvellez1, M. Andersen Jr1, T. Pearl1, K. El Jurdi1, D. B. Rubin1, A. Mayampurath2, D. T. Rubin1

Created: Friday, 22 February 2019, 9:41 AM
P580 Irritable bowel syndrome in inflammatory bowel disease after remission: correlation with remission patterns and inflammation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. Sezgin1, B. Boztepe2, E. Altintas1, D. Çelikcan3

Created: Thursday, 30 January 2020, 10:12 AM
P580: Benchmarking IBD Pharmacy Services to optimise, strengthen and align IBD Expert Pharmacy Practice
Year: 2021
Source: ECCO'21 Virtual
Authors: St Clair Jones, A.(1);Meade, U.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P580: Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort study
Year: 2022
Source: ECCO'22
Authors: de Voogd, F.(1);Bots, S.(1);Gecse, K.(1);Gilja, O.H.(2);D'Haens, G.(1);Nylund, K.(2);
Created: Friday, 11 February 2022, 3:56 PM
P580: Improvement in disease activity is associated with less disability in a prospective study of paediatric transition patients with IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Picardo*1, R. Panaccione1, G. Kaplan1,2, C. Seow1,2, J. deBruyn3, Y. Leung1,4

Created: Friday, 22 February 2019, 9:41 AM
P580: Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Balint A.*1, Torocsik D.1, Palatka K.2, Szepes Z.1, Szucs M.3, Ferenci T.4, Nagy F.1, Farkas K.1, Fábián A.1, Bor R.1, Milassin A.1, Rutka M.1, Molnar T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P580: Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Friedberg, S.(1)*;Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Krugliak Cleveland, N.(1);Rubin, D.T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P580: Vitamin D substitution dose in IBD patients: Higher than recommended?
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Kojecky1*, J. Matous2, Z. Zadorova3, P. Kohout4

Created: Thursday, 21 February 2019, 9:14 AM
P581 Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn’s disease: First real-life experiences
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P.O. Schreiner1, L. Biedermann1, G. Rogler1, M. Turina2, D. Cabalzar2

Created: Thursday, 30 January 2020, 10:12 AM
P581: Complementary and alternative therapies for inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. M. Fennessy*1, C. Hanna1, N. Breslin1, D. Mc Namara1,2, S. Anwar1, A. O'Connor1,2, B. M. Ryan1,2

Created: Friday, 22 February 2019, 9:41 AM
P581: Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn's disease: European multicentre study with a propensity-score matched analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Revés, J.(1)*;Fernandez-Clotet, A.(2);Ordás, I.(2);Buisson, A.(3);Ellul, P.(4);Elorza, A.(5);Aduna, M.(6);Rodríguez-Lago, I.(5);Freire, G.(7);Sousa, P.(7);Primitivo, A.(7);Delgado, I.(7);Sousa Lajas, I.(8);Raimundo, A.(8);Bettencourt, P.(8,9);Rimola, J.(10);Torres, J.(1,11);
Created: Friday, 14 July 2023, 11:05 AM
P581: Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Scaioli E., Sartini A., Bellanova M., Campieri M., Festi D., Bazzoli F., Belluzzi A.

Created: Wednesday, 20 February 2019, 10:36 AM